164 related articles for article (PubMed ID: 26685097)
41. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
Andrieu JM; Colonna P
J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
[No Abstract] [Full Text] [Related]
42. A sinister itch: prurigo nodularis in Hodgkin lymphoma.
Seshadri P; Rajan SJ; George IA; George R
J Assoc Physicians India; 2009 Oct; 57():715-6. PubMed ID: 20329432
[TBL] [Abstract][Full Text] [Related]
43. The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management.
Hawkes EA; Wotherspoon A; Cunningham D
Leuk Lymphoma; 2012 Mar; 53(3):354-61. PubMed ID: 21812538
[TBL] [Abstract][Full Text] [Related]
44. Vinblastine for elderly and frail patients with Hodgkin lymphoma.
Meynard L; Galtier J; Favre S; Debus L; Lascaux A; Dilhuydy MS; Gros FX; Sauvezie M; Milpied N; Bouabdallah K; Dimicoli S
Leuk Lymphoma; 2020 Dec; 61(13):3239-3242. PubMed ID: 32716269
[No Abstract] [Full Text] [Related]
45. Two Cases of Successful Autologous Hematopoietic Stem Cell Harvest after Treatment with Brentuximab Vedotin.
Kojima M; Ogiya D; Kawai H; Miyamoto M; Ohmachi K; Ogawa Y; Nakamura N; Ando K
Acta Haematol; 2015; 134(3):181-2. PubMed ID: 26022650
[No Abstract] [Full Text] [Related]
46. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.
Hartridge-Lambert SK; Schöder H; Lim RC; Maragulia JC; Portlock CS
Cancer; 2013 Mar; 119(6):1203-9. PubMed ID: 23132361
[TBL] [Abstract][Full Text] [Related]
47. Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma.
Della Pepa R; Picardi M; Giordano C; Zacheo I; Pugliese N; Cerchione C; Raimondo M; Di Perna M; Troncone G; Ciancia G; Intrieri M; Pane F
Br J Haematol; 2018 Sep; 182(5):715-718. PubMed ID: 28737231
[No Abstract] [Full Text] [Related]
48. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
[TBL] [Abstract][Full Text] [Related]
49. Pulmonary lymphocyte-rich classical Hodgkin lymphoma with early response to ABVD therapy.
Honda A; Nakamura F; Nannya Y; Shintani Y; Fukayama M; Ichikawa M; Kurokawa M
Ann Hematol; 2014 Jun; 93(6):1073-4. PubMed ID: 24173088
[No Abstract] [Full Text] [Related]
50. [No general recommendation for waiving consolidated radiotherapy in Hodgkin lymphoma and negative PET results after completion of chemotherapy].
Kriz J; Eich HT
Strahlenther Onkol; 2016 Aug; 192(8):595-6. PubMed ID: 27316375
[No Abstract] [Full Text] [Related]
51. Angiokeratoma corporis diffusum in a patient with Hodgkin lymphoma: a new paraneoplastic skin manifestation?
Han F; Wang P; Li Z; Zheng JH; Wang Q; Xu AE; Wang ZM
Br J Dermatol; 2013 Jun; 168(6):1351-3. PubMed ID: 23278357
[No Abstract] [Full Text] [Related]
52. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
53. Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma.
Cheah CY; Mistry HE; Konoplev S; Fowler NH
Leuk Lymphoma; 2016 Aug; 57(8):1974-6. PubMed ID: 26762971
[No Abstract] [Full Text] [Related]
54. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
Russo F; Corazzelli G; Frigeri F; Capobianco G; Aloj L; Volzone F; De Chiara A; Bonelli A; Gatani T; Marcacci G; Donnarumma D; Becchimanzi C; de Lutio E; Ionna F; De Filippi R; Lastoria S; Pinto A
Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
[TBL] [Abstract][Full Text] [Related]
55. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.
Pinnix CC; Smith GL; Milgrom S; Osborne EM; Reddy JP; Akhtari M; Reed V; Arzu I; Allen PK; Wogan CF; Fanale MA; Oki Y; Turturro F; Romaguera J; Fayad L; Fowler N; Westin J; Nastoupil L; Hagemeister FB; Rodriguez MA; Ahmed S; Nieto Y; Dabaja B
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):175-82. PubMed ID: 25863764
[TBL] [Abstract][Full Text] [Related]
56. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
[TBL] [Abstract][Full Text] [Related]
57. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.
Böll B; Görgen H; Fuchs M; Pluetschow A; Eich HT; Bargetzi MJ; Weidmann E; Junghanß C; Greil R; Scherpe A; Schmalz O; Eichenauer DA; von Tresckow B; Rothe A; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Apr; 31(12):1522-9. PubMed ID: 23509310
[TBL] [Abstract][Full Text] [Related]
58. Hodgkin's disease associated cholestasis in a man with thymoma.
Opeskin K; Burke M; McCaffrey G; Nandurkar H
Pathology; 2003 Aug; 35(4):349-51. PubMed ID: 12959773
[No Abstract] [Full Text] [Related]
59. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
60. [The practice of chemotherapy with the DeVita protocol].
Gassmann W; Schmitz N; Löffler H
Dtsch Med Wochenschr; 1982 Jul; 107(27):1063-9. PubMed ID: 6177488
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
